Press Releases July 16, 2026 04:05 PM

Empro Group Inc. Notified of Anticipated Delisting from The Nasdaq Stock Market

Empro Group Inc. Faces Delisting from Nasdaq Following Trading Suspension

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
EMPG

Empro Group Inc. has been notified by Nasdaq of its imminent delisting from the Nasdaq Stock Market effective July 27, 2026, unless the company appeals the decision. This action follows a prior trading suspension mandated by the U.S. Securities and Exchange Commission and a subsequent halt of trading by Nasdaq since October 23, 2025. Empro Group’s securities will remain halted and may trade over-the-counter if delisted.

Empro Group Inc. Notified of Anticipated Delisting from The Nasdaq Stock Market
EMPG
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Nasdaq has formally notified Empro Group Inc. of its planned delisting slated for July 27, 2026, unless appealed.
  • Trading in Empro Group's shares remains halted following a suspension by the SEC in late 2025.
  • If delisted, Empro Group’s shares may shift to trading on the over-the-counter market, impacting liquidity and investor accessibility.

NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market (Nasdaq: NDAQ) announced today that it has notified Empro Group Inc. (Nasdaq: EMPG) that its securities will be delisted from the Nasdaq Stock Market LLC on July 27, 2026, unless the company appeals to a Listing Qualifications Hearings Panel. The securities will remain halted, and unavailable to trade, until any appeal is resolved. Following removal from Nasdaq the securities may be eligible for trading in the over-the-counter market. 

Following a temporary trading suspension in the Company’s securities by the U.S. Securities and Exchange Commission (https://www.sec.gov/files/litigation/suspensions/2025/34-104166-ts.pdf) Nasdaq halted trading in the Company’s ordinary shares on October 23, 2025. Nasdaq has now determined that it is appropriate to use its authority under IM-5101-4 to delist the Company’s securities from Nasdaq.

For news and additional information about the company, please review the companies’ public filings or contact the company directly.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. Nasdaq’s rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: https://listingcenter.nasdaq.com/rulebook/nasdaq/rules/nasdaq-5800-series.  


Risks

  • Delisting from Nasdaq may reduce investor confidence, liquidity, and access to capital markets for Empro Group.
  • Continued regulatory scrutiny as evidenced by SEC suspension poses ongoing compliance and reputational risks.
  • Trading suspension and delisting may adversely affect the company's valuation and ability to attract new investors.

More from Press Releases

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM Aug 30, 2026 Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 Aug 29, 2026 Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 Aug 29, 2026 20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity Aug 28, 2026 Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update Aug 28, 2026